



## Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma

Guest Editors:

**Dr. Thierry Massfelder**

**Dr. Philippe Barthélémy**

**Dr. Valerian Dormoy**

**Dr. Mamatha Garige**

Deadline for manuscript  
submissions:

**closed (30 December 2023)**

### Message from the Guest Editors

Dear Colleagues,

Immune checkpoints are key regulators of the immune system and protect the host from autoimmune responses. Immune checkpoints can also be expressed on the surface of tumor cells and promote an immunosuppressive microenvironment that supports tumor growth. The blockade of immune checkpoints restores the activation of the immune system towards tumor cells. Multiple ICIs have been approved by the FDA for RCC therapies, including monoclonal antibodies that target the cytotoxic T-lymphocyte-associated protein-4 (CTLA-A4) or the programmed death-1 (PD-1). These antibodies are efficient and safe as monotherapy, in combination with other ICIs or with anti-angiogenic therapeutic compounds (the therapeutic references for 15 years). Thus, therapies based on ICIs are now recommended as the first-line therapy in clear-cell cancers with the observation of long-lasting disease control.

Dr. Thierry Massfelder

Dr. Philippe Barthélémy

Dr. Valerian Dormoy

Dr. Mamatha Garige

*Guest Editors*





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI